West Pharmaceutical Services (WST) Gross Profit (2009 - 2026)

West Pharmaceutical Services (WST) has reported Gross Profit for 18 consecutive years, with $329.2 million the latest figure, recorded in Q2 2026.

• Quarterly Gross Profit rose 20.19% year-over-year to $329.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.2 billion (up 17.21% YoY) and the FY2025 annual result came in at $1.1 billion, up 10.57% from the prior year.
• Gross Profit rose to $329.2 million in Q2 2026 per WST's latest filing, from $296.4 million in the prior quarter.
• Over the last five years, Gross Profit for WST reached as high as $329.2 million in Q2 2026 and fell as low as $230.0 million in Q2 2024.
• A 5-year average of $277.4 million and a median of $276.0 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2024 — Gross Profit decreased 21.07% — and 2026, when it advanced 27.81%.
• Year by year, Gross Profit stood at $262.1 million in 2022, then gained by 6.14% to $278.2 million in 2023, then slipped by 1.65% to $273.6 million in 2024, then rose by 11.07% to $303.9 million in 2025, then climbed by 8.33% to $329.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $329.2 million, $296.4 million, and $303.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.